CERUS CORP (CERS)
Health Care · Blood product safety and pathogen inactivation · NASDAQ
Cerus develops pathogen-inactivation technologies for blood transfusions and cellular therapy products, with the INTERCEPT Blood System as its lead commercial offering.
What CERUS CORP does
Cerus Corporation manufactures and commercializes the INTERCEPT Blood System, a proprietary technology platform designed to inactivate pathogens (viruses, bacteria, and parasites) in blood products to enhance transfusion safety. The company is also developing a red blood cell system for transfusion applications. Cerus generates revenue through direct sales and distribution partnerships in the U.S. and international markets, while pursuing regulatory approvals for product extensions and new indications.
Themes: ["transfusion safety","pathogen inactivation","blood products","regulatory advancement","cell therapy"]
Fundamentals
- Price$3.15 as of 2026-07-09 close
- Market cap$629M as of 2026-07-10
- 1-year return+111.4% as of 2026-07-09 close
- Net margin-3.9% as of 2026-07-10
- Gross margin+58.4% as of 2026-07-10
- ROE-15.4% as of 2026-07-10
- Debt / equity1.26 as of 2026-07-10
- Revenue growth (YoY)+18.4% as of 2026-07-10
- Revenue CAGR (3y)+7.5% SEC XBRL
- Beta1.75 as of 2026-07-10
Key risks (from latest filing)
["Dependence on sole-source suppliers for critical components of the INTERCEPT Blood System, creating supply chain vulnerability","Regulatory approval risk for the red blood cell system and existing product extensions, including CE Mark approval and FDA PMA submissions","Market adoption and commercialization challenges in the U.S. and international markets, coupled with inability to transition from third-party distribution models"]
Competitors & peers
- Grifols (GRFS)
- Haemonetics Corporation (HAE)
- Fresenius Kabi
- Bio-Rad Laboratories (BIO)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.